Baird lowered the firm’s price target on ResMed (RMD) to $300 from $320 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q3 results.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed Inc. Reports Strong Q1 Earnings Amid Growth Challenges
- ResMed price target raised to $299 from $298 at KeyBanc
- ResMed price target raised to $305 from $304 at Morgan Stanley
- Resmed’s Strong Growth and Future Potential: Buy Rating Affirmed
- ResMed price target lowered to $300 from $310 at Mizuho